

UTW-17

How to Read the Drug Profiles

- **General information**

This section includes the history of the product (first approval, originator company and brand name), relevant WHO guidance, world sales of the originator and basic patent information.

- **Table on price information - Developing Country Prices As Quoted by Companies**

Price

All prices are quoted in United States Dollars (US\$). Currency conversions were made on the day the price information was received using the currency converter site www.oanda.com. Prices are rounded up to the third decimal for unit price and to the nearest whole number for yearly price per patient (ppy).

The annual cost of treatment per patient year has been calculated according to the WHO dosing schedules multiplying the unit price (one tablet, capsule or millilitre) by the number of units required for the daily dose, and by 365. The price of the smallest unit is included in brackets.

For paediatric treatments, prices are calculated for a 10kg child using recommended dosing based on the 10 to 10.9 kg weight band, as it appears in the WHO paediatric antiretroviral treatment guidelines. This is an estimate, as the weight of a child increases during any given year. When it was not possible to calculate the dose for a 10kg child, only the unit price is indicated.

Within the tables, the information on the paediatric formulations is highlighted in pink in order to allow an easier distinction between adults and paediatric formulations.

Quality

Products quality-assured by WHO Prequalification Programme or US FDA (as of June 2014) are in **BOLD** in the tables of drug prices.

Readers and purchasers wishing to obtain more information about the quality of ARVs are encouraged to consult the WHO Prequalification Programme website and the US FDA website for approved and tentatively approved ARVs, as these lists are updated regularly.

Categories 1 and 2 Access to price discounts

When originator companies apply discounted prices on ARVs, each has different eligibility criteria. This means that a country that is eligible for a price discount from one company may be excluded from the list of eligible countries by another company. Every company defines its own list of category 1 and 2 countries. Please refer to annex 2

To know whether a country is eligible for a discounted price offered by a given company, or to find out in which category a given country is placed by different companies, please refer to the annexes.

- **Price Changes Over time – Chart on the Evolution of the lowest price quoted for developing countries**

This chart shows the price evolution over time, for both originator and generic products, as quoted to MSF for the purpose of this document.

The graph shows the lowest-priced generic product which is quality-assured by WHO Prequalification Programme or US FDA.

- **Spotlight on access issues- a look at patents and paediatrics**

The most salient issues related to access to each product are summarised here. The focus is on the availability of products, their affordability and their adaptability for the developing world.

Two additional sections have been included to discuss and highlight specific issues with regard to **patents** and **paediatrics**.